ArticleImmunotherapy2025

ROCKET: a phase 3 program evaluating the efficacy and safety of rocatinlimab in moderate-to-severe atopic dermatitis.

Emma Guttman-Yassky et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.